Although photocoagulation and intensive control

of systemic metabolic factors have been reported to achieve improved outcomes in large randomized clinical trials (RCTs), some patients with DME continue to lose vision despite treatment. Pharmacotherapies for DME include locally and systemically administered agents. We review several agents that have been studied for the treatment of DME.”
“Effective light management is imperative in maintaining high efficiencies as photovoltaic PND-1186 manufacturer devices become thinner. We demonstrate a simple and effective method of enhancing light trapping in solar cells with thin absorber layers by tuning localized surface plasmons in arrays of Ag nanoparticles. By redshifting the surface plasmon resonances by up to 200 nm, through the modification of the local dielectric environment of the particles, we can increase the optical absorption in an underlying Si wafer fivefold at a wavelength of 1100 nm and enhance the external quantum efficiency of thin Si solar cells by a factor of 2.3 at this wavelength where transmission losses are prevalent. Additionally, by locating the nanoparticles on the rear of the solar cells, we can avoid absorption losses below the resonance wavelength due to interference effects, while still allowing long wavelength

light to be coupled into the cell. Results from numerical simulations support the experimental findings and show that the fraction of light backscattered into the cell by nanoparticles Selleck Small molecule library located on the rear is comparable to the forward scattering effects of particles on the front. Using nanoparticle self-assembly methods and dielectrics commonly used in photovoltaic fabrication this technology is relevant for application to large-scale photovoltaic devices. (C) 2009 American Institute of Physics. [DOI: 10.1063/1.3140609]“
“Diabetic nephropathy (DN) is the leading cause of end-stage renal disease. The use of experimental models of DN has provided valuable information regarding many aspects of selleck chemical DN, including pathophysiology,

progression, implicated genes, and new therapeutic strategies. A large number of mouse models of diabetes have been identified and their kidney disease was characterized to various degrees. Most experimental models of type 2 DN are helpful in studying early stages of DN, but these models have not been able to reproduce the characteristic features of more advanced DN in humans such as nodules in the glomerular tuft or glomerulosclerosis. The generation of new experimental models of DN created by crossing, knockdown, or knockin of genes continues to provide improved tools for studying DN. These models provide an opportunity to search for new mechanisms involving the development of DN, but their shortcomings should be recognized as well. Moreover, it is important to recognize that the genetic background has a substantial effect on the susceptibility to diabetes and kidney disease development in the various models of diabetes.